News & Press

Media

Keyword search
Year
Bioworld: Abbisko out-licenses pimicotinib to Merck KGaA in $605M deal
Dec 12,2023
Endpoints: Abbisko signs $70M upfront deal with Merck KGaA for PhIII cancer drug
Dec 05,2023
FierceBiotech:Merck KGaA buys into Abbisko’s late-stage joint tumor med for $70M upfront
Dec 05,2023
Bioworld: Abbisko reports first-in-human data for homegrown FGFR4 inhibitor and PD-L1 inhibitor
Oct 18,2023
TIME: The FDA has approved the CSF-1R inhibitor Pimicotinib (ABSK021) of Abbisko Therapeutics to enter the Pivotal Global Multi-center Phase III Clinical Trial.
Mar 17,2023
HEALTHY GEM:Abbisko Therapeutics Announces An Out-License Agreement With Allist For ABK3376
Mar 17,2023
Bioworld:FDA grants breakthrough therapy designation to Abbisko's CSF­ 1R inhibitor, pimicotinib
Jan 30,2023
Bioworld:Abbisko out-licenses preclinical EGFR candidate to Allist for $188M
Mar 03,2023
AP NEWS: Abbisko Therapeutics announces that US FDA has granted breakthrough therapy designation for its CSF-1R inhibitor Pimicotinib(ABSK021)
Jan 31,2023
TIME: Abbisko Therapeutics Obtains Approval from The China NMPA to Conduct a Phase II Clinical Study of Pimicotinib (ABSK021) in cGVHD
Jan 19,2023
Abbisko Therapeutics Obtained ABSK091 IND Approval from NMPA
Dec 14,2020
Abbisko Therapeutics’ Partner X4 Pharmaceuticals Presented Positive Clinical Data from Phase 2 Study of Mavorixafor in WHIM Syndrome
Jun 19,2020
Abbisko Therapeutics Completes Dosing of the First Patient Cohort for ABSK-021 and The First Patient Enrollment for ABSK-011
Apr 07,2020
Abbisko Therapeutics Enters into Licensing Agreement with AstraZeneca for Development and Commercialization of AZD4547
Nov 08,2019

Tel:(+86) 021-68912098

E-Mail:Bd@abbisko.com
    PR@abbisko.com
    IR@abbisko.com

Copyright © 2021 All rights reserved:Abbisko Therapeautics     沪ICP备17056565号-1